Categories

Above the Fold

POLICY: If You Can’t Beat Them, Beat Them Back By Thomas Leith

The Wall Street Journal reported in a June 13th article,
  Page D1
that several major insurers (Aetna, Cigna, Humana, UnitedHealth)
  as well as Medicare are disclosing the prices they have negotiated with doctors
  and hospitals for a number of common procedures. Some are beginning to include
  quality indicators with the pricing information. This is an apparently-growing
  trend that may spell doom for companies like HealthGrades,
  but this wasn’t noted in the article. One interesting thing: apparently at least
  a few insured people have used the system, even though they’ll be well past
  the deductible. Maybe some few will note a link between the premiums they pay  and the Medical Loss Ratio their insurer experiences. On the other hand, the
  article notes that in the absence of any other quality indicator, people may
  think that more expensive implies higher quality and choose the
  high-cost provider.

The insurer’s tools are restricted to their own plan members: this means if
  you’re covered through Cigna you can’t tell what out-of-pocket costs might be
  for somebody covered by (say) United. The article goes on to detail several
  of the limitations inherent in these disclosures, well-known to readers of The
  Healthcare Blog. Tools like these might actually be useful to those with HDHP
  coverage, or the uninsured.

But there’s more. The article says states are beginning to mandate that hospitals
  disclose their charges. Charges amount to the "list price" that almost
  nobody pays, so this isn’t very helpful to prospective patients. The list includes
  South Dakota, Minnesota, and Florida. I wonder who got the states to mandate
  that instead of something useful. Some state hospital associations are evidently
  taking proactive measures, and have created their own websites to disclose hospital
  charges before being told they must. But why would they do this?

Look at this from the New Hampshire Hospital
  Association PricePoint system
:

How much do government programs pay compared to other payment
sources?
In many cases, Medicare & Medicaid reimburse hospitals at rates that do not
cover the costs they incur to provide care. Payments from privately insured
patients generally subsidize the shortfalls created by Medicare and Medicaid
and therefore represent a “hidden tax” on individuals and families not
covered by government programs.

Where have we heard this before?

When you ask for prices, you get median and mean charges with no promise that
  your bill will bear any resemblance to either figure, and this editorial.
  Apparently, they expect they’ll be forced to disclose someday, and this way
  they can control the content of the disclosure. If the legislature gets involved
  the hospitals might not be allowed to put their own "spin" on things. This actually
  is brilliant strategy. They’re not disclosing very much, but they can claim
  they’re being as transparent as they can be, given the vagaries of medical treatment.
  They can lobby commercially-insured patients to lobby congress to increase Medicare
  reimbursements with an implication that the amount they pay in "hidden taxes"
  will go down. But of course it won’t. They do not mention that there are many
  cases for which Medicare & Medicaid reimburse hospitals at rates that exceed
  the costs they incur to provide care. Imagine! Finally, they offer no assurances
  that the costs they incur to provide care are reasonable.

POLICY: The Three Percent Myth By Eric Novack M.D.

As the premier health policy blog on the net, I am honored that Matthew has asked me to occasionally guest post here. I also am regularly impressed with
  the level of thought and knowledge of so many posters of comments.
  Every once in a while, I think it is important to review, what I would believe
  so basic myths about our healthcare system. One of the greatest myths is the
  3% overhead myth for medicare. (This is often also cited as the 2% overhead
  myth.)
  Argument one in favor of the ‘medicare for all’ expansion of government
  regulated healthcare is the disparity in overhead between Medicare and private
  insurance plans. The Medicare overhead number is stated as 2% or 3%, depending
  upon where you read it. The overhead for private insurers is stated as 15%-25%.
  The disparity is used to explain the statement that, “if we just take the
  amount spent on wasted overhead and apply it to medicare-for-all, we could easily
  pay for everyone to be covered”. Where does that math come from? Here’s
  the brief skinny:
  $2 trillion in healthcare. 50% from private sector= $1trillion. Reduce overhead
  by 15-20%= $150- $200 billion available.
  Oh, if it was so simple.
  Let’s attack the 3% myth.

Proponents say overhead should be calculated as: admin costs/ payout for services.
  However, medicare recipients use much more care, on average, than younger groups.
  So, for example (made up numbers), medicare recipients might use $5000 per year,
  while commercially insured people might use $3000 per year. If both groups consisted
  of 10,000 people, it would take the same amount of oversight, management, etc.,
  yet the perceived overhead to take care of the younger group would be much higher;
  or put the other way, medicare overhead would be much lower.Solution: calculate overhead on a ‘per enrollee’ scale. This alone
  accounts for 50% of the discrepancy in overhead between medicare and private
  payers. If you do not believe me, just check with the Kaiser Foundation research
  saying the same thing.
  Proponents focus on the low administrative costs, on the one hand, while denouncing
  the amount of fraud by hospitals, providers. This perhaps is because medicare  does not spend enough on administrative oversight of the program. This happens to be exactly what the GAO and the National Academy of Social Insurance has  said within the past 6 years. So, if medicare spent more on administration,
  the discrepancy would be decreased even further.
  Proponents fail to account that for every regulation, costs are incurred by
  providers to comply. The 100,000 plus pages of medicare regulations function
  as an unfunded mandate on providers. Currently, the coding is based on ICD-9,
  which has over 24,000 codes. ICD-10, slated to go into effect within the next
  2 years has over 207,000!!!! And does upgrading for the change count toward medicare overhead? Of course not.
  Proponents say that private insurance company rules would create as much hassle
  for providers. Perhaps, but we will never know since private insurance rules
  are based off of the medicare guidelines.
  Thus, the ‘medicare 3% myth’, is, in reality, just that: a myth.

But like most myths, true believers will never pay attention to facts.

PHARMA: Can There Be Too Many Cures for Cancer? by Maggie Mahar

Last week, an upbeat story
  in the New York Times
described how big pharmaceutical companies have discovered
  cancer. A few years ago, the article points out, companies like Pfizer, Glaxo
  and Wyeth had relatively little interest in what they saw as a "niche market."

While a great many people die of cancer, the disease takes so many different
  forms that each market is relatively small. Big Pharma generally would rather
  focus its research on diseases with a broad base-allergy medications, for example,
  are a big favorite (even if, according to the National
  Institute for Health Care Management
, most people taking allergy medications
  don’t actually suffer from allergies.)

Drugmakers also prefer drugs that customers can be counted on to take for many
  years. (There is a saying in the pharmaceutical industry: "A pill that
  cures is good. A pill that you take every day is better.") Cancer patients
  tend to "die within months," the Times pointed out, curtailing profits.

But recently, big drug-makers have begun to recognize that cancer drugs can
  be profitable-if the price is high enough:

". . . companies have discovered that some patients will tolerate prices
  of tens of thousands of dollars a year, " the Times observed, "making
  drugs for even rare cancers into big moneymakers. Gleevec, which is used primarily
  for two obscure cancers – chronic myelogenous leukemia and gastrointestinal
  stromal tumor – had sales last year of $2.2 billion."

The race to get on the cancer bandwagon could lead to a flood of "me too"
  drugs that duplicate each other, the article acknowledged. But from the standpoint
  of the patients there [are] never too many, cancer drugs, the article asserted,
  quoting Dr. Robert J. Motzer, a kidney cancer specialist at Memorial Sloan-Kettering
  Cancer Center in New York City.  After all, the more drugs there are in the
  pipeline, the better chance a patient has of finding one, or a combination,
  that will work for them. Besides "competition could . . . bring down prices,"
  the Times suggested.

Really? If so, that would be a first.

When it comes to healthcare, competition almost never leads to lower prices.
  In most markets, comparison shoppers reward quality at a lower price. But when
  you’re dying of cancer, you’re probably not hunting for a bargain-even if you’re
  paying 20% of the cost out of your own pocket.

More importantly, even if you wanted to compare cost and quality, how would
  you go about doing it? As anyone who has ever been seriously ill knows, the
  more you learn about the pros and cons of various treatments, the less certain
  you are likely to be as to which might be the best for you.

Ambiguity haunts medical care. In my newest book, (Money-Driven
  Medicine: The Real Reason Health Care Costs So Much
Harper/Collins, May
  2006 )," I quote Dr. Atul Gawande, who describes "uncertainty"
  as "the core predicament of medicine . . . the thing that makes being a
  patient so wrenching, being a doctor so difficult and being part of a society
  that pays the bills so wrenching."

A Boston surgeon and author of Complications: A Surgeon’s Notes On An Imperfect
  Science, Gawande is quick to admit that even the physician is often not at all
  sure as to the "best" treatment for a given condition. Little wonder
  that patients are not able to bring down prices by shrewdly picking the product
  that offers the best value.

As for the idea that when there are more drugs in the marketplace, patients
  stand a better chance of finding one that works, some physicians warn that too
  many new drugs only adds to the confusion in a marketplace where free market
  competition has turned into a free-for-all.

According to the Pharmaceutical Research and Manufacturers Association, some
  400 cancer drugs from 178 companies are now in clinical trials-and many oncologists
  complain that this is more cures than they can hope to keep track of.

A sign of the times: in 2004 the
  Times reported
that one session of the American Society of Clinical Oncology’s
  conference was titled "Therapy of Metastatic Colorectcal Cancer: What Do
  We Do with So Many Options?"

As each drug company races to fill its own pipeline, a fragmented industry
  spawns a dizzying array of half-way cures. Too many drugs shrink tumors-but
  don’t bring any mortality benefit. Meanwhile, too much competition and too little
  collaboration makes it difficult for oncologists to sort out which drugs are
  most effective alone, which should be used together-and in what sequence.

When I was writing Money-Driven Medicine Dr. Genie Kleinerman, chief of pediatrics
  at Houston’s M. D. Anderson Cancer Center, recalled how two companies refused
  to work together to help her prove that two of their drugs might do a better
  job of targeting malignant cells of osteosarcoma ( a bone cancer that occurs
  in children), if they were used in combination. In the lab, Kleinerman had shown
  that you could mix the two agents. Now, she needed the company to do clinical
  trials in order to win approval from the FDA.

"But the lawyers for the two companies couldn’t come up with an agreement
  on who would own the rights to the combination and who would pay for what,"
  Kleinerman recalled, still frustrated. "Today it would be the same situation
  -or probably worse. The pharmaceutical industry has become so protective of
  who owns the intellectual property. You probably couldn’t even get them to sit
  down at the same table."

Instead, companies pursuing parallel research squander millions producing tumor-shrinking
  drugs that, too often, offer "no
  improved survival, no better quality of life, no added safety
" according
  to one study in the British Medical Journal–though they almost always cost
  more.

And as the pharmaceutical industry’s big guns elbow their way into the cancer
  marketplace, peddling pills that cost tens of thousands for a course of treatment,
  they are gobbling up much-needed health care dollars. Paying for these drugs
  is straining the system. Two years ago, Bains & Company, a management consulting
  firm estimated
  that paying for all of the drugs in development would require $60 billion a
  year-up from $10 billion at the time.

"Who’s going to pay for that? It’s just going to become unaffordable,"
  said Elgar Peerschke, head of the North American health care practice at Bain.

Oncologists like Genie Kleinerman believe that if government gave drugmakers
  incentives to pool their research, they might be able to develop fewer, more
  effective and more affordable remedies at a lower cost. But that’s not how free
  market competition normally works-at least not according to the conventional
  wisdom of a market-driven health care system.

TECH: If he beeps, he’s clean Bob By John Irvine

“It’s really no different than a tamperproof passport you can carry all
the time,” Applied Digital CEO Scott Silverman, attempting to explain
why  his company’s proposal to use surgically
implanted RFID microchips to help keep tabs on immigrants is really not as
frightening as it sounds.  Silverman says Applied Digital subsidiary VeriChip wants to work
with the Department of Homeland Security to develop a guest worker program
using the technology. 

The VeriChip was approved by the Food and Drug
Administration for human use in 2002 but has not seen widespread usage in the
healthcare industry.  By way of contrast, the company claims the VeriChip has been implanted in about 30 million animals.

In an interview on Fox News several weeks ago, Silverman said
several congressional leaders have expressed interest in the idea of using the
technology for border control.

FOOTNOTED: It turns out that the Department of Homeland
Security may not be all that keen on the idea, anyway. A DHS sub-committee
released a report Wednesday which concludes that using RFID to track people is
probably not a good idea in the first place. The report, titled “The Use of
RFID for Human Identification
” by the Emerging Applications and Techology
Subcommittee, warns that potential privacy problems make the technology something the government should avoid for now. That conclusion
drew protests from the Information Technology Association of America (ITAA) ,
an industry trade group. While conceding
that privacy issues exist, a spokesman for the group blamed the negative review
on “insufficient industry expertise” on the panel…

Amazing the things you learn if you read magazines
with exciting titles like Government Technology. I’m hooked.

 

BLOGS: Medpundit quits

Damn–I never posted this when it happened last month! But I still mean it

—————

Medpundit stopped blogging last week.

Sydney drove me mad. We fought about ethics, politics and everything. But she inspired some of my best thinking.

She was (is) the doyen of medical blogging, and even when life got crazy she was the one doctor blogger I’d go back through mounds of posts to read.

She was the best. I genuinely think I read every post she wrote in the last three years. And I will miss her. Thanks, Syd.

CONSUMERS/HEALTH PLANS/HOSPITALS/TECH: Consumer comparison tools, not exactly wowing the world as yet

There’s a new report from CHCF, written by Katy Hendrickson at Forrester, it’s called  (pdf) Health Care Cost Comparison Tools: A market under construction. I’ve read it and it does suggest that something is slowly happening in the Submio/Health Grades world, but that it’s mostly about a few plans trying to steer consumers around based on quality….we are a long, long way from price transparency. Stll def worth a read if you’re all interested in consumerism, transparency or health care cost and quality. And apparently some of you are

There’s also a companion report out called Consumers in Health Care: Creating Decision-Support Tools That Work . I haven’t read that one yet. Comments please from anyone who does.

 

TECH: Conflict-of-interest! This is the best Modern Healthcare could do?

I greeted with glee an email from Modern Healthcare suggesting that there was some seedy goings on in the RHIO world. That article is called Conflict-of-interest questions arise over RHIOs. I was looking forward to the expose of fraud, graft and corruption. Frankly the article is pathetic, and an embarrassing attack on totally the wrong targets.

Essentially the article says that Molly Coye was tangentially involved in the steering of consulting work from the Cal RHIO which she basically started out of HealthTech, which she did start, to a consulting company called Health Alliant of which she was an unpaid Board Chair/Adviser. The article does note that Molly never got paid anything by Health Alliant and recused herself from the negotiations between Cal RHIO and Health Alliant. Meanwhile Blackford Middleton is also on the board of Health Alliant, as is Scott Wallace and apparently they at least approve and are damned by association.

Full disclosure; I know Molly and Blackford quite well, and am in general fans of theirs, so take what I say in that context. But frankly this article is clutching at straws.

Yes, Molly is influential in the whole RHIO movement. She put together the energy with David Brailer to start the whole national health IT initiative, and you can argue that much of the concept of small Federal money to kick-start the private sector came from her 2003 Health Affairs paper. Yes, Health Tech was funded primarily by big providers, and Molly used her contacts and influence to get them to pay to fund it—but I might modestly suggest that if they provided nothing in return, HealthTech’s membership would not have come back for year 2. Yet several years later they’re still there. Yes, given that HealthTech exists it was a natural venue for RHIO discussions in California. Yes, HealthTech (and CalRHIO, and, on a sadly much more modest scale, I) receive money from the California Health Care Foundation, but that’s to support work that is important to CHCF’s charter. And the article managed to miss the juiciest ridiculousity of all in that CHCF’s President is Molly’s ex-husband! Surely they could have made some hay there!

Health Alliant, which is largely run by Jeff Rose who’s been in the health IT game for a while, is making a little business out of helping fledgling RHIOs with strategic planning. But it is a little business, at most $4m this year—and given the low margins on that type of work I bet their profit is puny compared to just the overspend on expenses at King/Drew in Los Angeles, or what Deloitte billed at UC Davis. And it’s nothing compared to the mega-millions Blues of Tennessee and Blues of Florida spent  in the 1990s with Andersen Consulting developing software that never worked.

And most importantly, Molly bent over backwards to get out of the appearance of conflict of interest. I’m sure if she was raking it in somehow, we’d all be invited to spend time on her yacht.

Many among us may have doubts as to whether RHIOs will succeed, and whether this is all a waste of Foundation and taxpayer money. But that’s the way progress (such as it is) in American health care IT is made. The goals of the the RHIO movement are extremely laudable. That it exists at all is in no small part due to Molly (and Blackford and Scott Wallace). There were I assure you plenty of things they could have been doing in the last few years to get much richer if they’d chosen. But instead they spent their time in getting us some of the way towards those goals. How does that justify running a long story about a non-existent conflict of interest that made them no money (and probably had a negative opportunity cost)?

If they want to dig into Molly, perhaps they should look into her appointment to the Board of Aetna. Although one only needed to look at their 10K to find out about that. Sadly for her she doesn’t appear yet to have the $400K in Aetna stock that the Directors need to own (and persumably not sell when they’re still directors) according to Aetna’s by-laws. They gave her a bunch of options for being on the board. I’m not exactly sure from my reading of the document whether it was a gift rather than she had to buy in. Perhaps Jack Rowe can lend her some cash if she’s short.

But even that seems very minor compared to just some of the Board appointments in health care. Don’t you think she could have got herself on the board of any and every health IT company in the nation if she’d really wanted to cash in?

There are plenty of potential conflicts of interest with board appointments in health care. Roy Poses doesn’t have Modern Healthcare’s resources, but  he manages to snare one or more from time to time including having a go at some clear board gadlfy’s like Uwe Reinhardt.

As for real malfeasance in health care? It’s just hard to imagine that Modern Healthcare couldn’t find somewhere better to look.

POLICY: Last shot of the Cannon?

Michael Cannon has written a response to my response to him. Even ignoring the issue about my personal HSA, we’re really talking past each other. Cannon doesn’t think our discussion is fruitful, and in truth it’s not. He wants to discuss the vast majority of his paper which looks at the role of HSAs within our current system. To me our current system is so broken, the introduction of HSAs (at least in the limited form they now exist which is all we’re likely to get for now) is pretty irrelevant, and a minor incremental change—albeit one away from the compulsory social insurance that, he correctly states, I advocate. Frankly in the next five years neither of us is going to get our way…so this argument is about what comes next.

The argument I want to have is a theoretical one about what would happen if we had essentially a completely personalized account-based system, as he advocates in his Large HSA proposal. As I explained at length before, I think that a significant number of people would take the money and by no or minimal insurance coverage. So apparently does he.

Large HSAs would give workers far greater freedom of choice. Workers could use their HSA funds (and non-HSA funds) to purchase insurance from their employer or any other source. Alternatively, they could forgo insurance to build larger HSA balances.

Now lets just assume that over say 20 years people really do build up huge HSA balances, and so when they need the money for their individual health crisis in year 20, they can pay for it all themselves. Even accepting that this would happen and that young healthies (His “students”) could buy a cheap heavily underwritten very high deductible policy for the early years, my question is what would happen in Year One? The money that would cover the sick in a compulsory social insurance pool, would have been extracted and instead be sitting in the personal accounts of the “students”. So when the sick start incurring huge health care costs, the money to pay them must come from somewhere. Unless the people who get sick had already saved up the huge amount they need or were allowed to buy into the cheap underwritten catastrophic plans, (both of which are totally unrealistic and the latter of which would destroy those plans as a profitable business), then that money must come from the taxpayer, or the providers (in the form of non-payment for services rendered).

This is the problem that I just don’t understand about the individual account theory. This is after all about the crux of insurance, which Cannon believes can work in a voluntary, HSA-based system. I just wish someone promoting those accounts would explain why I don’t understand how they overcome that issue rather than continually ignoring it.

 

assetto corsa mods